CNTX
Context Therapeutics Inc.Healthcare·Biotechnology
$2.85
$262M market cap
Revenue
$0.0M
Free Cash Flow
$-20.4M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin
2-Year Price History
$2.60+52.0%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -9.3 | -9.3 | -8.7 | -11.4 | -11.5 | -0.0 | 54.5 | 0.3 | 95.2 | -329.0% | -- | -- |
| Act | 2025-Q4 | 0.0 | -13.8 | -13.8 | -13.0 | -8.9 | -8.9 | -0.0 | 66.0 | 0.1 | 91.9 | -279.4% | -- | -- |
Valuation & Metrics
Market Stats
Price$2.85
Market Cap$262M
Enterprise Value$208M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-7.8%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-21.7M
Free Cash Flow$-20.4M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-304.2%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares0.9M
Days to Cover1.0
Change (vs Prior)+4.1%
Need at least 2 settlement dates for chart
Employees
Headcount12
Revenue / Employee$0
Gross Profit / Employee$-3,009
Cash Runway
32.1months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
79.5%(+61.1% YoY)
47 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
6.6%(+5.2% YoY)
7 filers
Vanguard, iShares, SPDR
Market makers
1.9%(+1.9% YoY)
5 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| MPM BioImpact LLC | $28.0M | $1.05 | +$0 | −$10.5M | -1.8% | $1.29B |
| Nextech Invest, Ltd. | $19.4M | $0.61 | +$0 | +$0 | +26.8% | $1.42B |
| Deep Track Capital, LP | $19.4M | $2.01 | +$0 | +$0 | -1.2% | $4.85B |
| Soleus Capital Management, L.P. | $18.2M | $2.62 | +$18.2M | +$18.2M | -0.9% | $2.47B |
| Octagon Capital Advisors LP | $13.8M | $2.62 | +$13.8M | +$13.8M | +0.9% | $904M |
| Blue Owl Capital Holdings LP | $13.3M | $1.69 | −$6.1M | −$6.0M | -2.3% | $372M |
| Avidity Partners Management LP | $13.1M | $1.83 | −$1.3M | −$6.5M | -8.2% | $505M |
| FRANKLIN RESOURCES INC | $10.0M | $1.47 | −$524K | −$524K | -0.2% | $403.03B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $9.0M | $2.62 | +$9.0M | +$9.0M | — | $4.04T |
| MARSHALL WACE, LLP | $7.7M | $1.57 | +$931K | +$7.7M | +0.6% | $92.71B |
| TCG Crossover Management, LLC | $7.0M | $2.62 | +$7.0M | +$7.0M | +4.6% | $3.50B |
| GREAT POINT PARTNERS LLC | $5.9M | $2.01 | −$6.4M | −$6.4M | -4.6% | $408M |
| MILLENNIUM MANAGEMENT LLC | $3.7M | $1.49 | −$3.1M | +$3.6M | -0.5% | $127.40B |
| Squadron Capital Management LLC | $2.9M | $2.62 | +$2.9M | +$2.9M | +17.5% | $250M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLPMM | $2.9M | $2.55 | +$2.8M | +$2.9M | -0.6% | $77.14B |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $2.6M | $2.62 | +$2.6M | +$2.6M | -0.1% | $64.61B |
| Sio Capital Management, LLC | $2.4M | $2.00 | −$1.1M | −$1.1M | -1.2% | $694M |
| BlackRock, Inc.Passive | $2.2M | $1.90 | −$4K | −$6K | -0.2% | $5.69T |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $1.6M | $1.87 | −$12K | −$93K | +2.3% | $1.61T |
| Cormorant Asset Management, LLC | $1.4M | $2.62 | +$1.4M | +$1.4M | -2.4% | $1.95B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
+2.23%
avg per quarter
Holders (ex-self)
+2.20%
excl. this stock
Buyers (this Q)
+1.92%
32 buyers · $0.07B in
Sellers (this Q)
-4.05%
16 sellers · $-0.01B out
alpha coverage: 95% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-2.4%
how holders react when this stock falls
On quiet Qs
-29.2%
−10% to +10% baseline
On rallies (+10%+)
+3.9%
how they react when this stock rises
Holders' portfolio flow this Q
+4.1%
inflows — adds are organic
Sellers' portfolio flow this Q
-4.9%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-3.2%
Holder mid (any stock)
-5.3%
Holder rally (any stock)
-6.4%
Biggest decreases this quarter
GREAT POINT PARTNERS LLC−$6.4Mα-4.6Blue Owl Capital Holdings LP−$6.1Mα-2.3Blackstone Group L.P.exited−$3.6MMILLENNIUM MANAGEMENT LLC−$3.1Mα-0.5Alyeska Investment Group, L.P.exited−$2.4MAvidity Partners Management LP−$1.3Mα-8.2Woodline Partners LP−$1.1Mα-0.1Sio Capital Management, LLC−$1.1Mα-1.2FRANKLIN RESOURCES INC−$524Kα-0.2Walleye Capital LLCexited−$195K
New buyers this quarter
Soleus Capital Management, L.P.+$0.02Bα-0.9Octagon Capital Advisors LP+$0.01Bα+0.9VANGUARD CAPITAL MANAGEMENT LLC+$0.01BTCG Crossover Management, LLC+$0.01Bα+4.6Squadron Capital Management LLC+$0.00Bα+17.5ADAGE CAPITAL PARTNERS GP, L.L.C.+$0.00Bα-0.1Cormorant Asset Management, LLC+$0.00Bα-2.4VANGUARD FIDUCIARY TRUST CO+$0.00BGOLDMAN SACHS GROUP INC+$0.00Bα-0.2
Top-5 holders · 50.9%
MPM BioImpact LLC--
Nextech Invest, Ltd.--
Deep Track Capital, LP--
Soleus Capital Management, L.P.--
Octagon Capital Advisors LP--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
MPM BioImpact LLC10.7MNextech Invest, Ltd.7.4MDeep Track Capital, LP7.4MSoleus Capital Management, L.P.7.0MGREAT POINT PARTNERS LLC2.2MAvidity Partners Management LP5.0MNextech Invest Ltd.—Octagon Capital Advisors LP5.3MBlue Owl Capital Holdings LP5.1MFRANKLIN RESOURCES INC3.8MMARSHALL WACE, LLP2.9MTCG Crossover Management, LLC2.7MBlackstone Group L.P.—
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
Analyst Coverage
Analyst Coverage
Analyst Ratings
6
Buy: 6Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Officers & directors
Buys ($, 12mo)
$107K
3 txns · 3 insiders · 160,010 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2025-06-09 | BUY | Lehr Martin A. | director, officer: Chief Executive Officer | 100,000 | $0.70 | $70K | $645K |
| 2025-06-06 | BUY | Levit Alex C. | officer: Chief Legal Officer, Corp. Sec | 20,000 | $0.58 | $12K | $17K |
| 2025-06-06 | BUY | Minai-Azary Jennifer Lynn | officer: Chief Financial Officer | 40,010 | $0.64 | $25K | $51K |
Order Flow (FINRA, ~3w lag)
28.9%retail-3.5pp
21.8%dark+3.1pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
CNTX: A Dilution Engine Disguised as a Clinical-Stage Pipeline
Overall Risk
7/10
Fraud
2/10
Dilution
9/10
Insolvency
4/10
Earnings Overstated
2/10
Hidden Liabilities
6/10
Legal
3/10
Audit Warnings
5/10
Hidden Upside
4/10
Contextually Acceptable
8/10